Loading stock data…
BNTX
$97.54-5.91 (-5.71%)
Market ClosedLast close May 1
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioNTech SE in the Healthcare sector is trading at $97.54. The stock is currently 21% below its 52-week high of $124.00, remaining 4.9% below its 200-day moving average. Technical signals show neutral RSI of 51 and bearish MACD signal, explaining why BNTX maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$97.54
Potential Upside
5%
Whystock Fair Value$102.42
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus18 analysts
Buy
Mean target$131.23+34.5%
Range$75.75 – $174.36
Fundamentals
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$27.63B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.59
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-5.91%
Volume
Today's trading volume
983,677
Recent News
European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading
European equities traded in the US as American depositary receipts were trending lower late Monday m
BioNTech SE (BNTX) PT Slightly Raised as Morgan Stanley Updates Biopharma Coverage Models
We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. BioNTech SE is among the best biotech stocks. TheFly reported on April 10 that Morgan Stanley slightly increased its price target on BNTX from $125 to $126 while maintaining an Overweight rating. The adjustment was part of broader updates […]
Why BioNTech (BNTX) Is Up 9.2% After Strong Phase 2 HER2 ADC Data In Endometrial Cancer
Earlier in April 2026, BioNTech reported positive primary Phase 2 results for its HER2‑targeted antibody-drug conjugate trastuzumab pamirtecan in previously treated, advanced endometrial cancer, showing clinically meaningful responses across all HER2 expression levels with a manageable safety profile and supporting its ongoing Phase 3 program. The strength of these data, together with existing Fast Track and Breakthrough Therapy designations and plans for a biologics license application in...
BioNTech (BNTX) Price Target Raised Following Successful T-Pam Data
BioNTech SE (NASDAQ:BNTX) is included among the 10 Best Global Stocks to Buy According to Wall Street Analysts. BioNTech SE (NASDAQ:BNTX) is a global biopharmaceutical company pioneering novel investigative therapies for cancer and infectious diseases. On April 13, BofA raised its price target on BioNTech SE (NASDAQ:BNTX) from $128 to $130, while maintaining a ‘Buy’ […]
BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains?
BioNTech (BNTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.